R

    Rein Therapeutics Inc (RNTX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.75
    -0.01 (-1.60%)

    Market Cap: $65.74M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    50%(17/34)
    Avg Surprise
    -41.83%
    Streak
    2 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.10
    Range$-0.10 - $-0.10
    2 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate Drift
    90d ago$-0.35-250.0%
    60d ago$-0.10+0.0%
    30d ago$-0.10+0.0%
    7d ago$-0.09+10.0%
    Current$-0.10
    Revenue Consensus
    $0
    Range$0 - $0
    2 analysts
    Dec 31, 2026
    EPS Consensus$0.30
    Range$0.29 - $0.31
    2 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    2 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.30---
    Sep 26EST
    		-$-0.10---
    Jun 26
    		$-0.10N/A+62.96%Beat+64.3%
    Mar 26
    		$-0.19N/A+61.22%Beat+24.0%
    Dec 25
    		$-1.22$-0.21-467.44%Miss-366.9%
    Sep 25
    		$-0.21$-0.24+12.50%Beat+22.2%
    Jun 25
    		$-0.28$-0.22-27.27%Miss+37.8%
    Mar 25
    		$-0.25$-0.21-19.05%Miss+70.9%
    Dec 24
    		$-0.26$-0.48+45.56%Beat+83.0%
    Sep 24
    		$-0.27$-0.35+22.86%Beat+32.5%
    Jun 24
    		$-0.45$-0.42-7.14%Miss-14.4%
    Mar 24
    		$-0.86$-1.02+15.69%Beat+18.1%
    Dec 23
    		$-1.54$-0.16-862.50%Miss-54.0%
    Sep 23
    		$-0.40$-0.20-100.00%Miss+71.4%
    Jun 23
    		$-0.39N/AN/ABeat+78.1%
    Mar 23
    		$-1.05$-0.60-75.00%Miss+41.7%
    Dec 22
    		$-1.00$-1.34+25.37%Beat-1150.0%
    Sep 22
    		$-1.40$-1.60+12.50%Beat+0.0%
    Jun 22
    		$-1.80$-1.90+5.26%Beat-50.0%
    Mar 22
    		$-1.80$-1.60-12.50%Miss-12.5%
    Dec 21
    		$-0.08$-0.08+0.00%Beat+33.3%
    Sep 21
    		$-1.40$-1.40+0.00%Beat+46.2%
    Jun 21
    		$-1.20$-1.40+14.29%Beat+57.1%
    Mar 21
    		$-1.60$-1.10-45.45%Miss+66.7%
    Dec 20
    		$-0.12$-0.13+5.81%Beat+53.8%
    Sep 20
    		$-2.60$-2.75+5.45%Beat+53.6%
    Jun 20
    		$-2.80$-3.73+24.93%Beat+46.2%
    Mar 20
    		$-4.80$-4.20-14.29%Miss+51.0%
    Dec 19
    		$-0.26$-0.27+3.70%Beat+97.4%
    Sep 19
    		$-5.60$-4.75-17.89%Miss+56.3%
    Jun 19
    		$-5.20$-4.45-16.85%Miss+50.0%
    Mar 19
    		$-9.80$-7.75-26.45%Miss-8.9%
    Sep 18
    		$-10.00$-11.10+9.91%Beat-20.9%
    Jun 18
    		$-12.80$-10.40-23.08%Miss-
    Mar 18
    		$-10.40$-10.00-4.00%Miss-
    Sep 17
    		$-9.00$-6.90-30.43%Miss-
    Jun 17
    		$-8.27$-8.20-0.85%Miss-

    Key Metrics

    Valuation
    P/E Ratio-0.44EV/EBITDA-0.64x
    Price/FCF-2.67xFCF Yield-37.43%
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-96.40%ROICN/A
    Financial Health
    Debt/EquityN/AInterest Coverage-49.68x
    Current Ratio4.27xQuick Ratio4.27x
    Trading Statistics
    Beta1.37Avg Volume459.92K
    52-Week High$2.1852-Week Low$0.69

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$0.79
    SMA 20$0.79
    SMA 50$0.86
    SMA 200$1.17
    EMA 10$0.78
    EMA 20$0.80
    EMA 50$0.86
    EMA 200$1.13

    MACD

    Line: -0.02Signal: -0.02Hist: 0.00

    ADX

    ADX: 15.6+DI: 14.2-DI: 13.9

    Aroon & PSAR

    Aroon Up64.0
    Aroon Down28.0
    PSAR$0.85

    Bollinger Bands

    Upper Band$0.85
    Lower Band$0.73
    %B Position1420%(Upper)
    Band Width0.14

    RSI (14-Day)

    Neutral
    40.2

    Momentum Oscillators

    Stoch %K8.6
    Stoch %D20.8
    Williams %R-95.9
    ROC (10d)-10.9%
    Momentum-0.09
    CCI (20d)-142.7
    MFI (14d)46.6

    Volatility Measures

    ATR (14d)$0.06(8.2%)
    StdDev (20d)0.03
    Hist Vol65.6%(High)

    Volume Flow

    VWAP$0.76
    OBV34.2M
    AD Line-27.9M
    CMF (20d)-0.320

    Volume Metrics

    Avg Vol (20d)476.0K
    Vol Ratio1.1x
    VWMA (20d)$0.78

    Pivot Points

    R3$0.81
    R2$0.80
    R1$0.78
    Pivot Point$0.77
    S1$0.75
    S2$0.74
    S3$0.73

    Advanced Oscillators

    TSI-10.79
    Ultimate Osc40.1
    KST-62.37

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$0$0$0$0$0$0
    Cost of Revenue$0$0N/A$0$0$0N/A$0$0$0N/A$0
    Gross Profit$0$0N/A$0$0$0N/A$0$0$0N/A$0
    Operating Expenses$6.08M$5.23M$32.66M$5.49M$6.87M$5.61M$42.80M$6.07M$9.04M$7.21M$7.29M$1.98M
    R&D$3.64M$3.07M$2.00M$1.68M$4.29M$3.05M$3.32M$3.72M$3.74M$3.46M$1.97M$22,000
    SG&A$2.44M$2.16M$1.96M$3.81M$2.58M$2.56M$2.48M$2.35M$5.30M$3.74M$5.33M$1.96M
    Operating Income$-6,076,000$-5,230,000$-32,659,000$-5,492,000$-6,871,000$-5,609,000$-42,797,000$-6,071,000$-9,039,000$-7,205,000$-7,290,000$-1,983,000
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$299,000$608,000$20,000$89,000$0$0$0$0$0$0$49,000$0
    Income Before Tax$-6,375,000$-5,838,000$-32,679,000$-5,581,000$-6,822,000$-5,501,000$-42,525,000$-5,847,000$-8,942,000$-7,113,000$-7,339,000$-1,827,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-6,375,000$-5,838,000$-31,967,000$-5,581,000$-6,822,000$-5,501,000$-40,981,000$-5,847,000$-8,942,000$-7,113,000$-7,339,000$-1,827,000
    EBITDA$-5,923,000$-5,215,000$-32,679,000$-5,581,000$-6,821,000$-5,501,000$-42,525,000$-5,847,000$-8,938,000$-7,054,000$-7,099,000$-1,816,000
    EBIT$-6,375,000$-5,838,000$-32,679,000$-5,581,000$-6,822,000$-5,501,000$-42,525,000$-5,847,000$-8,942,000$-7,113,000$-7,339,000$-1,827,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about RNTX

    News

    Rein Therapeutics Receives U.S. FDA Fast Track Designation for LTI-03 in Idiopathic Pulmonary Fibrosis

    Rein Therapeutics announced that its drug candidate LTI-03 has received U.S. FDA Fast Track designation for the treatment of idiopathic pulmonary fibrosis (IPF). This designation will facilitate faster development and review of LTI-03, which is currently in Phase 2 trials and aims to not only slow disease progression but also support tissue repair and regeneration. The company expects to report interim data from the RENEW Phase 2 trial in the second half of 2026.

    GlobeNewswire•8/21/26•
    Bullish

    Rein Therapeutics receives FDA fast track for IPF drug LTI-03

    Rein Therapeutics has been granted Fast Track designation by the FDA for its idiopathic pulmonary fibrosis (IPF) drug, LTI-03. This designation will expedite the development and review process for the inhaled peptide therapy, which is currently in a Phase 2 clinical trial across multiple countries. The drug aims to inhibit lung scarring and preserve alveolar progenitor cells in IPF patients, a condition with limited effective treatments.

    Investing.com Australia•8/21/26•
    Bullish

    Rein Therapeutics Receives U.S. FDA Fast Track Designation for LTI-03 in Idiopathic Pulmonary Fibrosis

    Rein Therapeutics announced that the U.S. FDA has granted Fast Track designation to LTI-03 for the treatment of idiopathic pulmonary fibrosis (IPF), highlighting the urgent need for new therapies beyond slowing disease progression. This designation facilitates expedited development and review for serious conditions with unmet medical needs. The company is actively enrolling patients in its RENEW Phase 2 trial and expects to report interim data in the second half of 2026 for LTI-03, a first-in-class inhaled peptide therapy designed to inhibit lung scarring and promote tissue repair.

    Yahoo Finance•8/20/26•
    Bullish

    Rein Therapeutics receives FDA fast track for IPF drug LTI-03

    Rein Therapeutics has been granted Fast Track designation by the FDA for its idiopathic pulmonary fibrosis (IPF) drug, LTI-03. This designation aims to accelerate the development and review process for LTI-03, an inhaled peptide therapy designed to inhibit lung scarring. The company is currently enrolling patients in a global Phase 2 trial and expects to release interim data in the second half of 2026.

    Investing.com Canada•8/20/26•
    Bullish

    Rein Therapeutics Receives FDA Fast Track Designation for LTI-03 in Idiopathic Pulmonary Fibrosis

    Rein Therapeutics has been granted FDA Fast Track designation for LTI-03, its drug for idiopathic pulmonary fibrosis (IPF), which will expedite its development and review. LTI-03 is a novel inhaled peptide therapy designed to slow lung scarring and promote healing, currently in a Phase 2 trial with interim data expected in the second half of 2026. This designation highlights the urgent need for new IPF treatments, as current therapies only slow disease progression.

    Quiver Quantitative•8/20/26•
    Bullish

    Frequently Asked Questions About RNTX

    Does RNTX pay dividends?
    Rein Therapeutics Inc (RNTX) does not currently pay a regular dividend.
    What is RNTX's market cap?
    Rein Therapeutics Inc (RNTX) has a market capitalization of $65.74M with a current stock price of $0.75.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In